This protocol addresses pityriasis rosea occurring during pregnancy — a setting where the patient's immune status warrants specific clinical consideration.
Pregnant women are more susceptible to pityriasis rosea because of their altered immune response, which influences both the clinical presentation and the approach to management.
An antiviral approach may be considered in this setting. The complete protocol — including specific indications, clinical decision points, and all relevant parameters — is available behind the link below.
Pregnant women are more susceptible to pityriasis rosea because of their altered immune response.
Treatment with acyclovir can be considered, although more studies are needed to clarify its potential benefits.
View source ↗